Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG.

UNLABELLED Recently, the thymidine analog 3'-deoxy-3'-(18)F-fluorothymidine (FLT) was suggested for imaging tumoral proliferation. In this prospective study, we examined whether (18)F-FLT better determines proliferative activity in newly diagnosed lung nodules than does (18)F-FDG. METHODS Twenty-six patients with pulmonary nodules on chest CT were examined with PET and the tracers (18)F-FDG and (18)F-FLT. Tumoral uptake was determined by calculation of standardized uptake value (SUV). Within 2 wk, patients underwent resective surgery or had core biopsy. Proliferative activity was estimated by counting nuclei stained with the Ki-67-specific monoclonal antibody MIB-1 per total number of nuclei in representative tissue specimens. The correlation between the percentage of proliferating cells and the SUVs for (18)F-FLT and (18)F-FDG was determined using linear regression analysis. RESULTS Eighteen patients had malignant tumors (13 with non-small cell lung cancer [NSCLC], 1 with small cell lung cancer, and 4 with pulmonary metastases from extrapulmonary tumors); 8 had benign lesions. In all visible lesions, mean (18)F-FDG uptake was 4.1 (median, 4.4; SD, 3.0; range, 1.0-10.6), and mean (18)F-FLT uptake was 1.8 (median, 1.2; SD, 2.0; range, 0.8-6.4). Statistical analysis revealed a significantly higher uptake of (18)F-FDG than of (18)F-FLT (Mann-Whitney U test, P < 0.05). (18)F-FLT SUV correlated better with proliferation index (P < 0.0001; r = 0.92) than did (18)F-FDG SUV (P < 0.001; r = 0.59). With the exception of 1 carcinoma in situ, all malignant tumors showed increased (18)F-FDG PET uptake. (18)F-FLT PET was false-negative in the carcinoma in situ, in another NSCLC with a low proliferation index, and in a patient with lung metastases from colorectal cancer. Increased (18)F-FLT uptake was related exclusively to malignant tumors. By contrast, (18)F-FDG PET was false-positive in 4 of 8 patients with benign lesions. CONCLUSION (18)F-FLT uptake correlates better with proliferation of lung tumors than does uptake of (18)F-FDG and might be more useful as a selective biomarker for tumor proliferation.

[1]  J Bogaert,et al.  Lymph node staging in non-small-cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  P. Conti,et al.  Synthesis of 2'-fluoro-5-[11C]-methyl-1-beta-D-arabinofuranosyluracil ([11C]-FMAU): a potential nucleoside analog for in vivo study of cellular proliferation with PET. , 1995, Nuclear medicine and biology.

[3]  M. Berger,et al.  2-[C-11]thymidine imaging of malignant brain tumors. , 1999, Cancer research.

[4]  D. Wood,et al.  Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5]  L. Wiens,et al.  Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[6]  D. Harpole,et al.  Correlation of FDG-PET imaging with Glut-1 and Glut-3 expression in early-stage non-small cell lung cancer. , 2001, Lung cancer.

[7]  P C Goodman,et al.  Staging non-small cell lung cancer with whole-body PET. , 1999, Radiology.

[8]  D K Owens,et al.  Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. , 2001, JAMA.

[9]  R. Blasberg,et al.  Imaging brain tumor proliferative activity with [124I]iododeoxyuridine. , 2000, Cancer research.

[10]  H. Dittmann,et al.  Early changes in [18F]FLT uptake after chemotherapy: an experimental study , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[11]  R L Wahl,et al.  Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. , 1999, Radiographics : a review publication of the Radiological Society of North America, Inc.

[12]  R L Wahl,et al.  Glucose transporters and FDG uptake in untreated primary human non-small cell lung cancer. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[13]  U. Haberkorn,et al.  [18F]FLT; portrait of a proliferation marker. , 2002, European journal of nuclear medicine and molecular imaging.

[14]  M. Schwaiger,et al.  Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[15]  L. Mortelmans,et al.  Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  V Kalff,et al.  (18)F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[17]  P. Dupont,et al.  Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  K. Ishiwata,et al.  Tracer feasibility for monitoring tumor radiotherapy: a quadruple tracer study with fluorine-18-fluorodeoxyglucose or fluorine-18-fluorodeoxyuridine, L-[methyl-14C]methionine, [6-3H]thymidine, and gallium-67. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[19]  Torsten Mattfeldt,et al.  3-deoxy-3-[(18)F]fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules. , 2002, Cancer research.

[20]  Paul J. van Diest,et al.  Biologic correlates of 18fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography , 2002 .

[21]  T. Ido,et al.  Microautoradiographic study for the differentiation of intratumoral macrophages, granulation tissues and cancer cells by the dynamics of fluorine-18-fluorodeoxyglucose uptake. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[22]  V Kalff,et al.  F‐18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinoma , 2001, Cancer.

[23]  A. Shields,et al.  Development of labeled thymidine analogs for imaging tumor proliferation. , 1996, Nuclear medicine and biology.

[24]  T. Mattfeldt,et al.  Ki-67 immunostaining in pancreatic cancer and chronic active pancreatitis: does in vivo FDG uptake correlate with proliferative activity? , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[25]  V Kalff,et al.  Clinical impact of (18)F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Johan Nuyts,et al.  Methods to monitor response to chemotherapy in non-small cell lung cancer with 18F-FDG PET. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[27]  F. O’Sullivan,et al.  2-[(18)F]Fluoro-2-deoxyglucose and glucose uptake in malignant gliomas before and after radiotherapy: correlation with outcome. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  H. Dosaka-akita,et al.  A risk-stratification model of non-small cell lung cancers using cyclin E, Ki-67, and ras p21: different roles of G1 cyclins in cell proliferation and prognosis. , 2001, Cancer research.

[29]  H. Tonami,et al.  FDG PET measurement of the proliferative potential of non-small cell lung cancer. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[30]  J. R. Grierson,et al.  Simplified Labeling Approach for Synthesizing 3′-Deoxy-3′-[18F]fluorothymidine ([18F]FLT) , 2000 .

[31]  Otto Muzik,et al.  Imaging proliferation in vivo with [F-18]FLT and positron emission tomography , 1998, Nature Medicine.

[32]  M. Schwaiger,et al.  Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.